JP2022516351A5 - - Google Patents

Info

Publication number
JP2022516351A5
JP2022516351A5 JP2021539418A JP2021539418A JP2022516351A5 JP 2022516351 A5 JP2022516351 A5 JP 2022516351A5 JP 2021539418 A JP2021539418 A JP 2021539418A JP 2021539418 A JP2021539418 A JP 2021539418A JP 2022516351 A5 JP2022516351 A5 JP 2022516351A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539418A
Other languages
English (en)
Japanese (ja)
Other versions
JP7512290B2 (ja
JP2022516351A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/050203 external-priority patent/WO2020144178A1/en
Publication of JP2022516351A publication Critical patent/JP2022516351A/ja
Publication of JP2022516351A5 publication Critical patent/JP2022516351A5/ja
Application granted granted Critical
Publication of JP7512290B2 publication Critical patent/JP7512290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539418A 2019-01-07 2020-01-07 抗tigit抗体 Active JP7512290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789466P 2019-01-07 2019-01-07
US62/789,466 2019-01-07
PCT/EP2020/050203 WO2020144178A1 (en) 2019-01-07 2020-01-07 Anti-tigit antibodies

Publications (3)

Publication Number Publication Date
JP2022516351A JP2022516351A (ja) 2022-02-25
JP2022516351A5 true JP2022516351A5 (https=) 2023-01-19
JP7512290B2 JP7512290B2 (ja) 2024-07-08

Family

ID=69177132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539418A Active JP7512290B2 (ja) 2019-01-07 2020-01-07 抗tigit抗体

Country Status (12)

Country Link
US (1) US12312401B2 (https=)
EP (1) EP3908609A1 (https=)
JP (1) JP7512290B2 (https=)
KR (1) KR20210113282A (https=)
CN (1) CN113993894B (https=)
AU (1) AU2020206588A1 (https=)
BR (1) BR112021013397A2 (https=)
CA (1) CA3125800A1 (https=)
IL (1) IL284584A (https=)
MX (1) MX2021008216A (https=)
SG (1) SG11202107474RA (https=)
WO (1) WO2020144178A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
EP4192883A4 (en) * 2020-08-05 2024-12-04 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
WO2022105872A1 (zh) * 2020-11-23 2022-05-27 广东菲鹏制药股份有限公司 抗tigit抗体或其抗原结合片段
AU2023264591A1 (en) 2022-05-02 2024-11-07 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
KR20250048558A (ko) * 2022-08-15 2025-04-09 엠브레이스 테라퓨틱스, 인크. 세포내 표적에 대한 항체를 생산하는 무세포 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tigitに対する抗体
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Tigit結合劑和彼之用途
CN108290936B (zh) 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
PE20181046A1 (es) 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
KR101837936B1 (ko) 2016-08-31 2018-03-13 송철기 금속 이온을 이용한 살균수 생성장치
WO2019023504A1 (en) * 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
KR101859195B1 (ko) 2017-10-13 2018-05-17 강선영 석션 기능을 갖는 ret방식 고주파 마사지기

Similar Documents

Publication Publication Date Title
JP2022516351A5 (https=)
JP2025111463A5 (https=)
JP2017535257A5 (https=)
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2017048240A5 (https=)
JP2020514310A5 (https=)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2015514110A5 (https=)
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
FI3740504T3 (fi) CD70-yhdistelmähoito
HRP20221083T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
JP2017514795A5 (https=)
JP2013542194A5 (https=)
JP2015535828A5 (https=)
JP2020502271A5 (https=)
JP2015504421A5 (https=)
JP2021510736A5 (https=)
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2012532851A5 (https=)
JP2017512759A5 (https=)
JP2015503909A5 (https=)
JP2022533538A5 (https=)
JP2022509156A5 (https=)
JP2020522280A5 (https=)